These preclinical data, together with clinical findings from CD19-targeting studies in B-lineage leukemia and lymphoma, highlight the role of tumor rejection kinetics mediated by different signaling domains and their importance in achieving durable tumor control. The gene discussed is CD19; the disease is neoplasm.